Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

JCO precision oncology·2026
Same author

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.

British journal of cancer·2026
Same author

Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.

Cancer research·2025
Same author

Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung Cancer.

JCO precision oncology·2025
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer.

Carmela Ciardullo1, Luis Tobalina1, T Hedley Carr1

  • 1AstraZeneca, Cambridge, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 11, 2025
PubMed
Summary
This summary is machine-generated.

Monitoring circulating tumor DNA (ctDNA) in extensive-stage small cell lung cancer (ES-SCLC) shows early treatment response and predicts relapse. ctDNA dynamics offer a sensitive marker for therapy efficacy and potential molecular relapse in ES-SCLC.

More Related Videos

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

16.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.5K

Related Experiment Videos

Last Updated: Sep 11, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

16.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.5K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options and poor patient outcomes.
  • Current monitoring methods for SCLC may not accurately reflect treatment response or predict relapse.
  • Circulating tumor DNA (ctDNA) analysis presents a promising, minimally invasive approach for disease monitoring.

Purpose of the Study:

  • To evaluate the utility of ctDNA for monitoring disease progression and assessing first-line therapy efficacy in extensive-stage SCLC (1L ES-SCLC).
  • To correlate ctDNA dynamics with treatment response and clinical outcomes in patients with 1L ES-SCLC.

Main Methods:

  • The TAZMAN trial enrolled 31 patients with 1L ES-SCLC receiving standard chemotherapy plus durvalumab.
  • Plasma samples (n=228) from 27 patients were analyzed for somatic mutations and copy number aberrations using a liquid biopsy approach.
  • Analysis accounted for clonal hematopoiesis (CH) mutations to distinguish them from tumor-derived alterations.

Main Results:

  • Baseline ctDNA detected somatic alterations in 96.3% of patients, predominantly in TP53 and RB1 genes.
  • Early treatment ctDNA dynamics showed significant reductions in variant allele frequency (VAF), indicating initial chemosensitivity.
  • Reduced ctDNA levels below the limit of detection predicted longer treatment duration and anticipated relapse before imaging, highlighting ctDNA's sensitivity.

Conclusions:

  • Early ctDNA dynamics provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC.
  • ctDNA analysis can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies.
  • Larger studies utilizing extended next-generation sequencing (NGS) panels are warranted to fully elucidate ctDNA's role in SCLC management.